MYRIAD GENETICS INC
No SEC Form 4 filings for $MYGN in the last 30 days.
See all $MYGN insider activity →Myriad Genetics (NASDAQ: MYGN) will report Q3 2026 earnings on November 4, 2026, with a conference call scheduled for the same day. The company promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026, following the departure of Brian Donnelly. Myriad reaffirmed its full-year 2026 financial guidance without providing updated figures.
Myriad Genetics (MYGN) and former Chief Commercial Officer Brian Donnelly finalized a separation agreement. Donnelly will receive a $1,322,294 lump-sum severance and accelerated vesting for time-based awards. The agreement is effective October 14, 2026, subject to revocation.
MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Se
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MYGN (MYRIAD GENETICS INC). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent MYGN coverage spans earnings, financial news and corporate actions.
Ahead of the Nov 4 after-close earnings release, traders will focus on whether reaffirmed FY 2026 guidance holds and how the new commercial leadership affects execution commentary.
The departure may cause modest short‑term pressure as investors assess leadership continuity.
The severance and accelerated equity vesting may cause modest share‑price pressure as investors assess the leadership change.
Disappointing earnings and guidance cause downside pressure.
Positive catalyst from partnership and potential future diagnostic revenue.
AlphAI scores every news story that mentions MYGN with an AI model for sentiment and relevance, and aggregates insider trades from MYRIAD GENETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Myriad Genetics (NASDAQ: MYGN) will report Q3 2026 earnings on November 4, 2026, with a conference call scheduled for the same day. The company promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026, following the departure of Brian Donnelly. Myriad reaffirmed its full-year 2026 financial guidance without providing updated figures.
2 min readMyriad Genetics (MYGN) and former Chief Commercial Officer Brian Donnelly finalized a separation agreement. Donnelly will receive a $1,322,294 lump-sum severance and accelerated vesting for time-based awards. The agreement is effective October 14, 2026, subject to revocation.
1 min readMYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Se
1 min readMyriad Genetics (MYGN) reported Q2 revenue of $190.7M, down 10.5% YoY, missing estimates. It lowered full-year guidance, causing its stock to drop 20.7%. Amgen (AMGN) reported $10.05B in Q2 revenue, up 9.5% YoY, beating estimates. Novavax (NVAX) reported $56.7M in Q2 revenue, down 76.3% YoY, but beat EPS estimates. Both AMGN and NVAX stocks rose post-earnings.
2 min readMyriad Genetics (NASDAQ:MYGN) and SOPHiA GENETICS (NASDAQ:SOPH) are collaborating with AstraZeneca (NYSE:AZN) to advance prostate cancer biomarker PrGIS. Myriad's MyChoice CDx test will produce the PrGIS score, and SOPHiA will integrate it into its cloud-based platform. The companies plan to present research at ESMO 2026.
2 min readMyriad Genetics (MYGN) stock rose 5% after Craig-Hallum analyst John Wilkin raised its price target to $8, reflecting an increased valuation estimate. The company's shares have been volatile, with a 46.1% drop in July 2026 due to disappointing earnings and reduced guidance. MYGN is down 30.5% year-to-date and trades 47.9% below its 52-week high.
2 min readIncyte (INCY) reported Q2 revenue of $1.67B, up 37.7% YoY, beating estimates by 11.3% but missing full-year guidance. Regeneron (REGN) saw revenue of $4.29B, up 16.7% YoY, exceeding expectations by 12.4%. Myriad Genetics (MYGN) reported $190.7M in revenue, down 10.5% YoY, missing estimates. Amgen (AMGN) reported $10.05B in revenue, up 9.5% YoY, beating expectations. Moderna (MRNA) reported $145M in revenue, up 2.1% YoY, exceeding estimates by 35.8%.
2 min readAmgen (AMGN) rose 9.5% post-earnings, trading at $225.10. Myriad Genetics (MYGN) reported a 10.5% revenue decline, missing estimates, and fell 25.3% to $4.01. Novavax (NVAX) beat expectations with a 76.3% revenue drop but gained 36.7% to $10.53. Halozyme Therapeutics (HALO) grew revenue 47.7%, beating estimates, and rose 31.5% to $112.81.
2 min readAbbVie (NYSE:ABBV) reported Q2 revenue of $16.99B, up 10.2% YoY, beating estimates by 1.2%. Biogen (NASDAQ:BIIB) saw revenue rise 3.4% YoY, exceeding expectations by 12.1%. Myriad Genetics (NASDAQ:MYGN) reported a 10.5% YoY revenue decline, missing estimates by 8.2%. Gilead Sciences (NASDAQ:GILD) reported $7.80B in revenue, up 10.2% YoY, beating estimates by 6.2%. Moderna (NASDAQ:MRNA) reported $145M in revenue, up 2.1% YoY, surpassing expectations by 35.8%.
3 min readMYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial SALT LAKE CITY , September 16, 2026 – Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promo
1 min read
